The European Medicines Agency is to review a regulatory submission from Swiss gene-editing specialist CRISPR Therapeutics and partner Vertex Pharmaceutical. 25 January 2023
Indian drugmaker Dr. Reddy’s Laboratories has completed the trial program for its proposed rituximab biosimilar candidate, and will move ahead with global regul 23 January 2023
Hematology specialist Disc Medicine has in-licensed certain antibodies from Mabwell Therapeutics, a division of Shanghai-based Mabwell Bioscience. 20 January 2023
Chinese biotech company Beigene has announced that the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for chronic lymphocytic leukem 20 January 2023
CAR-T cell therapy specialist CARsgen Therapeutics has inked a deal with a division of Huadong Medicine for the commercialization of CT053 in China. 17 January 2023
Nkarta, a US biopharma developing engineered natural killer (NK) cell therapies to treat cancer, has announced the appointment of a chief medical officer (CMO). 11 January 2023
Californian biotech Jasper Therapeutics has announced that it will focus on the development of its lead product candidate, briquilimab, in chronic diseases and 11 January 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.